Lyme Disease Diagnostic Devices Market Revenue, Diagnostic Testing Volume, Adoption Rates, Pricing Metrics, Supply Chain Performance, Market Share Analysis, and Innovation Trends

Revenue, 2025

USD 2.82 Bn

Forecast Year, 2035

USD 4.79 Bn

CAGR, 2026 - 2035

5.44%

Report Coverage

Global

What is the Lyme Disease Diagnostic Devices Market Size?

The global lyme disease diagnostic devices market size is accounted at USD 2.82 billion in 2025 and predicted to increase from USD 2.97 billion in 2026 to approximately USD 4.79 billion by 2035, expanding at a CAGR of 5.44% from 2026 to 2035.

Key Takeaways

• North America led the global market with the largest market share of 40% in 2025.
• By Product, the serological test segment has held the largest revenue share in 2025.
• By Product, the lymphocytic transformation tests segment is anticipated to expand at a significant CAGR during the projected period.
• By End User, the hospitals segment has held the largest revenue share in 2025.

What is the Lyme Disease Diagnostic Devices Market?

Upsurge in incidence of Lyme disease, growing policy attention on improving health care services, and the advent of new diagnostic tests for Lyme disease pushes the market. Nonetheless, lack of knowledge of the disease and ineffectiveness in Lyme disease research reduces the market. Additionally, growth in key players' interests in Lyme disease diagnosis R&D is predicted to provide lucrative business growth opportunities. Moreover, increasing number of cases of tick-borne infectious diseases is boosting Lyme disease diagnostics market. Vector-borne diseases are illnesses caused by pathogens and parasites in human inhabitants. Each year greater than 1 billion individuals are infected and higher than 1 million people die from vector-borne illnesses. They can be infected by bacteria, parasites or viruses. More than 16% of the ailment and disability endured globally is because of vector-borne illnesses, with more than 50% of world's population presently assessed to be at risk of these ailments.

How is AI contributing to the Lyme Disease Diagnostic Devices Market?

Artificial Intelligence is not only able to diagnose Lyme disease better but also faster. The technology behind AI makes the whole thing more efficient. For example, with deep learning, even very subtle signs of the disease can be recognized while using predictive analytics in outbreak monitoring and public health planning. AI is able to support the development of personalized diagnostic practices, and in turn, clinical settings become more efficient, less prone to manual interpretation errors, and very innovative.

Lyme Disease Diagnostic Devices Market Growth Factors

• Growing prevalence of Lyme disease
• Increasing number of cases of tick-borne infectious diseases
• Growing investment in research and development
• Technological advancement
  

Lyme Disease Diagnostic Devices Market Outlook

• Industry Growth Overview: Increasing awareness and rising disease burden are pushing the demand for advanced diagnostic devices that support improved clinical outcomes globally.
• Sustainability Trends: Sustainable development is a trend that emphasizes environmentally friendly analyzers and longer-lasting devices that promote responsible usage of diagnostic technology.
• Global Expansion: The adoption of improved testing has already begun in both the established and emerging markets, thus boosting international diagnostic capabilities.
• Major Investors: Roche, Abbott, Bio-Rad, DiaSorin, QIAGEN, and Thermo Fisher Scientific are always pursuing new, groundbreaking diagnostic innovations and bringing them into the market worldwide.
• Startup Ecosystem: The start-ups that are leading the way in the creation of new pathogen-detection techniques and the development of rapid point-of-care systems are, at the same time, forming collaborations with the established diagnostic companies that have a significant impact.

Market Scope

Segment Insights

Product Insights

Serological Test Segment Reported Foremost Market Stake in 2025

Serological test segment recorded the prime market share in the global Lyme disease diagnostic devices market by type in 2025. Increasing use in the early diagnosis of Lyme disease diagnostics is the major reason for high market share of serological test. Other factors such as increasing investment in research and development is expected to increase the usage of serological tests over the estimate period.

The lymphocytic transformation tests are projected grow at the highest CAGR during the forecast period mainly due to new product launches in the near future.

The lymphocytic transformation tests segment is expected to grow in the coming years. The concern of borrelia-based antibodies is unlocking the potential of the range of transformative products. The valuable diagnostic space and PCR expansion are confirming valuable activation of the device solution that drives precision into the lyme condition diagnostic process. The tick bite cases are elevating the antibiotic treatment that highly accelerates demand in the market in the responsible healthcare industries. The direct detection of the condition requires a precision level of transitioning diagnostic tools.

End User Insights

Hospitals are Projected to Dominate the End User Segment of Lyme Disease Diagnostic Devices Market Revenue

The Lyme disease diagnosis is based on infection signs and symptoms, history of exposures to infected black-legged ticks, and laboratory tests. Serological tests can take several weeks to become conclusive after infection, indicating the need for new diagnostic tests that can identify the earliest signs of infection. Hospitals are well-equipped to handle patient flow and employ latest diagnostic and treatment techniques. These factors are primarily responsible for the greater market share of hospitals in the end-user segment of the Lyme Disease Diagnostic Devices Market. Public/private laboratories segment will expand at a significant CAGR during the forecast time-frame.

The public/private laboratories segment is expected to expand during the forecast period due to the valuable test expansion as per the diagnostic needs. The testing engagements keep the laboratories' activities busy, which eventually fuels the market interaction, specifically in the centralized condition. The tech transition holds the power of advancement to the lab settings. Following this, the testing and devices chain is bolstering the segmental market. Leading to this, the expansion of automation and research reports is improving the lyme condition. The multiplex assays are gaining traction in the lab settings.

Regional Insights

North America is Estimated to be the Largest Market for Lyme Disease Diagnostic Devices

The research report covers key trends and prospects of Lyme disease diagnostic devices products across different geographical regions including North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa. Geographically, Lyme disease diagnostic devices market is conquered by North America owing to high incidence of Lyme disease and existence of state-of-the-art healthcare infrastructure. On the other hand, Asia-Pacific is anticipated to witness a rapid growth rate, on account of increasing research and development investment by major market players and increasing awareness regarding tick-borne infectious disorders.

U.S. Lyme Disease Diagnostic Devices Market Size and Growth 2026 to 2035

The U.S. lyme disease diagnostic devices market size is estimated at USD 790 million in 2025 and is predicted to be worth around USD 1,380 million by 2035, at a CAGR of 5.74% from 2026 to 2035.

How is North America leading in the Lyme Disease Diagnostic Devices Market?

The North American market is driven by the presence of competent healthcare systems, strong diagnostic implementation, and an increasing awareness of the disease. The region's growth is supported by the continued development of new technologies and research to improve early detection and management.

United States Lyme Disease Diagnostic Devices Market Trends

The United States has the advantage of government support that is strong, active research funding, and a considerable presence of diagnostic companies. Clear regulatory routes are a big plus for the innovation and research activities in the area of public health, which are also a big part of the reason for the latter innovations in the first place.

What are the driving factors of the Lyme Disease Diagnostic Devices Market in Europe?

Europe is a huge market, and it is characterized by high disease prevalence, increased awareness, and healthcare investment. The advancements in diagnostics, the setting up of common testing rules, and the breakthroughs in research are all playing their part in developing the market in the region, and the early detection capabilities are even being enhanced to a greater extent now.

France Lyme Disease Diagnostic Devices Market Trends

France is on the route of increasing demand backed up by vigorous research activity, especially in the area of innovative preventive solutions. The collaboration between the research institutions is signaling a new development in diagnostics, which is in line with the current emphasis the country is putting on disease identification and management tools.

How is Asia-Pacific performing in the Lyme Disease Diagnostic Devices Market?

The APAC market is going through a rapid expansion phase, which is being driven by the growing awareness, the better healthcare infrastructures, and the increase in research participation. The measures taken to enhance the accessibility of diagnostics and the creation of inexpensive solutions are in play across both urban and rural areas, thereby facilitating the fast growth of the market in those regions.

India Lyme Disease Diagnostic Devices Market Trends

There is a noticeable increase in the potential of India as a result of the growing research and awareness in the high-risk areas. The possibilities are the wide-reaching nature of the low-cost diagnostics, the incorporation of better tests in the public health systems, and the tackling of the underreporting issue through enhanced surveillance and outreach education programs.

MEA's Development in the Market

MEA market is considered to be a significantly growing area, due to its core development position in the regional medical sector featuring modernized nucleic acid tests and educational surveys that fuel enhancement in the lyme condition. The modernized laboratories enable device manufacturers to dig into the developmental scope of the diagnostic space. The medical advancement and modern infrastructure define the involvement of strong unification of the devices' interaction.

UAE Market Trends

UAE market trends are promoting the testing business, covering the imported testing solutions, highlighting the international expansion advantage to the countryside market trends. The popularity of effective devices accompanying the regional medical facilities empowers diagnostic innovations.

Lyme Disease Diagnostic Devices Market Value Chain Analysis

• R&D: Discovering new methods and technologies and researching to develop diagnostics and their components.
  Key Players: Abbott and Bio-Rad Laboratories
• Clinical Trials and Regulatory Approvals: Conducting tests for safety and effectiveness, followed by applying for necessary regulatory approvals.
  Key Players: Abbott, Bio-Rad, and Roche Diagnostics
• Formulation and Final Dosage Preparation: Manufacturing diagnostic reagents and combining electronic parts to create working diagnostic devices.
  Key Players: Thermo Fisher Scientific, DiaSorin S.p.A, and Meridian Bioscience
• Packaging and Serialization: Making packaging materials that can protect the product and assigning serial numbers for traceability, compliance, and efficient inventory management.
  Key Players: Quidel Corporation, Abbott Laboratories
• Distribution to Hospitals, Pharmacies: Routing logistics and organized delivery of the approved devices to health facilities and ultimately to users.
  Key Players: Quest Diagnostics and LabCorp

Competitive Landscape

The lyme disease diagnostic devices market is marked to be a part of centralized devices solution portfolio in complement to the multiplex testing platforms. The robust and comprehensive MTTTA streamline is a boon to market interaction in the responsible healthcare space. The valuable contributors such as Bio-Rad Laboratories, T2 Biosystems, Abbott Laboratories, Roche and Thermo Fisher Scientific are the backbone of market awareness, especially in the advance centralized diagnostic space. The tech boost and smart efforts of the modern leaders are exploring the niche of the devices spectrum for a validated range of device portfolio.

Lyme Disease Diagnostic Devices Market Companies

• Bio-Rad Laboratories, Inc.: Bio-Rad offers a full range of automated multiplex immunoassays for early and late-stage antibody detection through innovative system integration.
• Thermo Fisher Scientific, Inc.: Thermo Fisher has an advanced product line of instruments, reagents, and software tailored to support a variety of diagnostic applications and lab settings.
• Boulder Diagnostics: Boulder Diagnostics' SpiroFind test accurately identifies active Lyme disease by detecting the cellular immune response to the pathogen.

Other Major Key Players

• T2 Biosystems, Inc.
• Abbott
• Oxford Immunotec Global PLC
• Quidel Corporation
• Affymetrix Inc.
• Hoffmann-La Roche Ltd
• Graphene Frontiers

Recent Developments

• In October 2025, Twin brothers Jack and Will Goodreau launched Brothers Tick Kits, designed to safely remove ticks and protect families from tick-borne illnesses, inspired by their sister's Lyme disease fight. (Source: morningagclips.com)
• In March 2025, Antech launched truRapid™ FOUR, an in-house screening test for canine vector-borne diseases, detecting antibodies for Anaplasma, Ehrlichia, Lyme C6, and heartworm using whole blood, serum, or plasma. (Source: businesswire.com)

Segment Covered in the Report

By Product Type

• Serological Test
• Urine Antigen Tests
• Lymphocytic Transformation Test
• Immunofluorescent Staining
• Nucleic acid Test

By End User

• Hospitals
• Public/Private Laboratories
• Physician's Office

By Region

• North America
• Latin America
• Europe
• Asia-pacific
• Middle and East Africa